A Real-World Study on Hospital and Economic Burden of Dengue Fever in French Overseas Territories
Author(s)
Solenne Tauty, PharmD1, Samuel MARKOWICZ, MD2, Anouar Sahli, MSc3, Julie Cornebise, MSc4, Cédric STRUB, PharmD4, Francoise BUGNARD, MSc5, Franck Favre-Besse, PhD4, Cinira Lefevre, PhD6.
1Stève Consultants, Oullins, France, 2CHU Guadeloupe, Service des maladies infectieuses et tropicale, Guadeloupe, France, 3Steve consultants, Oullins, France, 4TAKEDA France, Paris, France, 5Cytel, Oullins, France, 6Data Value Generation & Health Economics, TAKEDA France, Paris, France.
1Stève Consultants, Oullins, France, 2CHU Guadeloupe, Service des maladies infectieuses et tropicale, Guadeloupe, France, 3Steve consultants, Oullins, France, 4TAKEDA France, Paris, France, 5Cytel, Oullins, France, 6Data Value Generation & Health Economics, TAKEDA France, Paris, France.
OBJECTIVES: The incidence of dengue fever (DF) significantly increased over the past years, representing a public health threat for endemic areas, such as French overseas territories where real-world data on the DF burden is lacking. This study aimed to describe the hospital burden and associated costs of dengue fever in French overseas territories.
METHODS: This retrospective observational study used the French national hospital database (PMSI) in 4 French overseas territories (Martinique, Guadeloupe, French Guiana [FG], and Reunion). Hospitalizations with a main diagnosis of DF were identified over the study period (Jan 2017-Dec 2023). The DF number and its hospitalizations rates per 100,000 all-cause hospitalizations by territory were calculated over the study period and within epidemic periods (EPs). Within EPs, patient characteristics, mean hospitalization duration stays, and associated costs were reported by age groups/territory.
RESULTS: During the study period, 7,020 hospitalized patients were identified, 96.8% of whom during EPs, across territories. Within EPs, hospitalizations rates were 3.1 times higher than during the overall study period (3.4 Martinique, 3.0 Guadeloupe/FG, and 2.6 Reunion). In each territory, the highest hospitalizations rates were observed within patients aged 5-19. Mean ages were 30.2, 26.8, 51.3 years, respectively for Martinique-Guadeloupe, FG, and Reunion; and proportion of men ranged from 42.5-48.3% across territories. Mean hospitalization duration was 4.6 days (min 3.2 FG; max 5.1 Reunion), 88% were hospitalized via emergency rooms (min 74.3% FG; max 91.8% Reunion), and related in-hospital death was <2%. Mean cost per DF hospitalization was €3,509 (min €2,070 FG; max €4,043 Reunion).
CONCLUSIONS: This real-world evidence study across French overseas territories showed that during EPs, the DF hospital burden is considerable, particularly within the year range 5-19. The economic burden varied across territories. As the epidemiology of dengue fever continues to progress worldwide, further studies should continue to monitor the overall burden of the disease.
METHODS: This retrospective observational study used the French national hospital database (PMSI) in 4 French overseas territories (Martinique, Guadeloupe, French Guiana [FG], and Reunion). Hospitalizations with a main diagnosis of DF were identified over the study period (Jan 2017-Dec 2023). The DF number and its hospitalizations rates per 100,000 all-cause hospitalizations by territory were calculated over the study period and within epidemic periods (EPs). Within EPs, patient characteristics, mean hospitalization duration stays, and associated costs were reported by age groups/territory.
RESULTS: During the study period, 7,020 hospitalized patients were identified, 96.8% of whom during EPs, across territories. Within EPs, hospitalizations rates were 3.1 times higher than during the overall study period (3.4 Martinique, 3.0 Guadeloupe/FG, and 2.6 Reunion). In each territory, the highest hospitalizations rates were observed within patients aged 5-19. Mean ages were 30.2, 26.8, 51.3 years, respectively for Martinique-Guadeloupe, FG, and Reunion; and proportion of men ranged from 42.5-48.3% across territories. Mean hospitalization duration was 4.6 days (min 3.2 FG; max 5.1 Reunion), 88% were hospitalized via emergency rooms (min 74.3% FG; max 91.8% Reunion), and related in-hospital death was <2%. Mean cost per DF hospitalization was €3,509 (min €2,070 FG; max €4,043 Reunion).
CONCLUSIONS: This real-world evidence study across French overseas territories showed that during EPs, the DF hospital burden is considerable, particularly within the year range 5-19. The economic burden varied across territories. As the epidemiology of dengue fever continues to progress worldwide, further studies should continue to monitor the overall burden of the disease.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH5
Topic
Economic Evaluation, Epidemiology & Public Health, Real World Data & Information Systems
Disease
Infectious Disease (non-vaccine)